机构:[1]Department of NuclearMedicine, The Affiliated Hospital of Southwest Medical University/Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province and Institute of NuclearMedicine, SouthwestMedical University, Luzhou, Sichuan, China
The authors declare that they have no
competing interests. This study was supported in part by research foundation
projects from Luzhou Science and Technology Department (20107 and
2022-JYJ-118), and The Affiliated Hospital of Southwest Medical University
(20087).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2024]版:
无
最新[2023]版:
大类|3 区医学
小类|3 区核医学
第一作者:
第一作者机构:[1]Department of NuclearMedicine, The Affiliated Hospital of Southwest Medical University/Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province and Institute of NuclearMedicine, SouthwestMedical University, Luzhou, Sichuan, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of NuclearMedicine, The Affiliated Hospital of Southwest Medical University/Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province and Institute of NuclearMedicine, SouthwestMedical University, Luzhou, Sichuan, China[*1]Department of Nuclear Medicine, The Affiliated Hospital of SouthwestMedical University, No. 25 TaiPing St, Jiangyang District, Luzhou, Sichuan, 646000, China
推荐引用方式(GB/T 7714):
Yang Hongyu,Liu Huipan,Zhang Yu,et al.Metastatic Lung Adenocarcinoma Received Combined 177 Lu-FAP-2286 Radiation Therapy and Targeted Therapy[J].Clinical Nuclear Medicine.2024,49(6):569-571.doi:10.1097/RLU.0000000000005169.
APA:
Yang Hongyu,Liu Huipan,Zhang Yu,Zhang Yu&Chen Yue.(2024).Metastatic Lung Adenocarcinoma Received Combined 177 Lu-FAP-2286 Radiation Therapy and Targeted Therapy.Clinical Nuclear Medicine,49,(6)
MLA:
Yang Hongyu,et al."Metastatic Lung Adenocarcinoma Received Combined 177 Lu-FAP-2286 Radiation Therapy and Targeted Therapy".Clinical Nuclear Medicine 49..6(2024):569-571